Biopharmaceutical News and Research

RSS

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR has been granted Orphan Drug Designation (ODD) by the European Medicines Agency for the treatment of acute myeloid leukemia (AML).

30 Oct 2014

GE Healthcare launches startup campus Health Innovation Village to help entrepreneurs speed up health tech solutions

Today GE Healthcare officially opens Health Innovation Village, its first health tech startup campus, at its Finnish headquarters with the Minister of Economic Affairs in Finland, Jan Vapaavuori and the Mayor of Helsinki, Jussi Pajunen.

29 Oct 2014

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'.

28 Oct 2014

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand.

27 Oct 2014

MPI Research announces acquisition of Jasper Clinical Research & Development

MPI Research today announced it has acquired the assets of Kalamazoo, Mich.-based Jasper Clinical Research & Development, Inc. Jasper is a respected clinical research organization that provides early-stage human clinical testing of promising new drugs, and is well known to pharmaceutical and biotechnology companies worldwide.

27 Oct 2014

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40).

23 Oct 2014

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).

22 Oct 2014

YEDA and XL-protein sign deal to commercialize PASylated IFN superagonis

YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist -- PAS-YNSα8 -- which has been jointly developed by scientists at the Weizmann Institute and XL-protein.

21 Oct 2014

Kalorama Information: Experimental vaccine distribution in the UK points to growing flu vaccine market

Kalorama Information believes an experimental vaccine distribution in the United Kingdom and other similar developments point to a growing flu vaccine market, as well as a growing market for the production of these vaccines.

16 Oct 2014

Imaxio, DKFZ partner to evaluate potential of IMX313 with candidate vaccine targeting HPV

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed.

15 Oct 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014

OBN, ABPI sign MoU to build a better public profile

13 October 2014, London and Oxford: The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK's emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding (MoU).

13 Oct 2014

Maker of experimental Ebola drug scales up

The manufacturer of the experimental Ebola drug ZMapp says it has put other business on hold since August to boost production of the medication. Meanwhile, news outlets look at the government's authority to screen airline travelers, the House action to release additional funding for disease-fighting efforts and the Dallas hospital's defense of its treatment of the West African man who died of the disease this week.

12 Oct 2014

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for companion diagnostics such as the drug-test combinations envisioned in this deal.

9 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.

9 Oct 2014

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

Ruthigen Inc., a biopharmaceutical company focused on pioneering new therapies to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures, announces the initiation of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

8 Oct 2014

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).

8 Oct 2014

Obama administration announces plans to step up airport screening for Ebola virus

Though President Barack Obama did not say exactly how screening procedures would change, the director of the Centers for Disease Control and Prevention said officials would consider a variety of options.

8 Oct 2014

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy.

7 Oct 2014

Biopharmaceutical News and Research

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

GE Healthcare launches startup campus Health Innovation Village to help entrepreneurs speed up health tech solutions

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

MPI Research announces acquisition of Jasper Clinical Research & Development

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

YEDA and XL-protein sign deal to commercialize PASylated IFN superagonis

Kalorama Information: Experimental vaccine distribution in the UK points to growing flu vaccine market

Imaxio, DKFZ partner to evaluate potential of IMX313 with candidate vaccine targeting HPV

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

OBN, ABPI sign MoU to build a better public profile

Maker of experimental Ebola drug scales up

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

Obama administration announces plans to step up airport screening for Ebola virus

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News